Introduction {#s1}
============

Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) are cytosolic innate immune sensors that recognize viral double-stranded (ds)RNAs. RLRs (RIG-I, MDA5 and LGP2) are members of the so-called Superfamily II (SF2) helicases/translocases. They share a multi-domain architecture that consists of a central SF2 ATPase domain accompanied by two N-terminal tandem caspase activation and recruitment domains (2CARD, only in RIG-I and MDA5) and a C-terminal regulatory domain (CTD or RD) ([@bib31]). The SF2 domain itself is built out of an N-terminal RecA-like domain (1A) and a C-terminal RecA-like domain (2A) that together form an ATP-binding pocket, as well as an insertion domain (domain 2B). SF2 and RD are crucial for RNA-recognition of RLRs, whereas 2CARD communicates successful RNA-binding events to downstream signaling factors ([@bib14]; [@bib18]; [@bib23]). Specifically, RIG-I detects dsRNA ends harbouring 5' tri- or diphosphates ([@bib12]; [@bib34]; [@bib35]). Simultaneous binding of an RNA ligand and ATP to RIG-I switches the protein into an active state in which the otherwise shielded 2CARD is released ([@bib47]). Activated RIG-I homo-tetramerizes via 2CARD ([@bib15]) and nucleates the polymerisation of its adapter protein, mitochondrial antiviral-signaling (MAVS), to elicit the innate immune signaling cascade ([@bib27]; [@bib43]).

The similarity of epitopes of viral RNA recognized by RLRs, in particular dsRNA stems, to some endogenous ribonucleic acids has required the immune system to develop mechanisms besides merely recognizing 5'-di/triphosphate-containing RNA ends to discriminate self from non-self. Self-ribonucleic acids for instance are shielded from RLRs by introducing 2'O-methylations or by destabilizing double-stranded parts through A-to-I editing ([@bib6]; [@bib9]; [@bib20]; [@bib38]). In addition, we and others have been able to show that the SF2 domain of RLRs itself confers a proof-reading activity by removing RIG-I from self-RNA so as to avoid autoimmunity ([@bib3]; [@bib19]; [@bib22]; [@bib30]). In particular, ATP turnover can lead to translocation on dsRNA stems that could remove the protein from the RNA and reinstall the inactivated state ([@bib25]; [@bib44]).

Deficiencies in any of these mechanisms can lead to immune recognition of self-RNAs ([@bib2]; [@bib5]). For instance, single-nucleotide polymorphisms (SNPs) in RLR genes are known to cause system-wide autoimmune diseases such as Aicardi-Goutière syndrome (AGS) ([@bib26]; [@bib32]), Singleton-Merten syndrome (SMS) ([@bib13]; [@bib33]), systemic lupus erythematosus (SLE) ([@bib8]; [@bib28]; [@bib41]) or type 1 diabetes ([@bib21]; [@bib40]). The molecular basis for the development of these diseases is in many cases not understood, because structural data on these RLR variants have been missing.

In this work, we present the biochemical and structural analysis of the RIG-I SMS variant C268F and unveil an ATP-independent signaling mechanism. We show that active site rearrangements of several amino acid side chains in RIG-I C268F mimic an ATP-bound state and activate the protein for signaling upon recognition of RNA ligands in the absence of ATP.

Results and discussion {#s2}
======================

The RIG-I SMS variants C268F and E373A are located within SF2 ATP binding and hydrolysis motifs I and II, respectively, ([@bib11]) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and were previously shown to be constitutively active in reporter cells without any external dsRNA trigger ([@bib13]; [@bib19]) ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). RIG-I E373A's enhanced immune signaling ability can be explained by proficient ATP binding but reduced ATP hydrolysis, since the motif II glutamate is implicated in positioning and polarizing the attacking water molecule in the hydrolysis reaction. The stabilized ATP state leads to increased binding of and activation by endogenous dsRNA ([@bib19]; [@bib22]). By contrast, the molecular basis for activation of RIG-I C268F is still unknown as this mutation is located in motif I, which is normally associated with ATP binding and which is critical for RIG-I activation. For instance, a designed and widely used mutant with a defect in the invariant ATP phosphate-binding motif I lysine, K270A, possesses reduced ATP binding properties ([@bib30]) and the RIG-I K270A/I mutant is deficient in inducing an immune response ([@bib19]; [@bib46]). By contrast, the RIG-I SMS variant C268F shows the opposite effect and is constitutively active, although this mutation is only two amino acids away from K270A in the same ATP phosphate-binding 'P-loop' in motif I ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}).

To analyze whether the autoimmune activity of the SMS variant RIG-I C268F is RNA-dependent, we designed a double-mutant that is defective in RNA-binding and carried out interferon (IFN)-β-promoter-driven luciferase reporter assays with overexpressed proteins in HEK293T RIG-I KO cells ([Figure 1A](#fig1){ref-type="fig"}). In particular, we used a previously described T347A point mutation in the RNA-binding interface of the N-terminal RecA-like domain (1A) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), that abrogates the signaling of wild type (wt) RIG-I in infected cells and decreases the affinity for dsRNA in vitro ([@bib19]). Our assays show, that RIG-I C268F, T347A fails to induce the IFN-β promoter in uninfected as well as in 19mer 5'-triphosphate (ppp)-dsRNA-stimulated cells, indicating that the RIG-I SMS single-mutant C268F induces immune signaling only if bound to endogenous or transfected RNA. In addition, competition assays of RIG-I C268F titrated with signaling-deficient RIG-I lacking the 2CARD domain (RIG-I Δ2CARD) or with RIG-I Δ2CARD E373Q also gradually decreased the IFN-β promoter-driven luciferase activity ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). Thus, RIG-I C268F as well as RIG-I Δ2CARD (E373Q) seem to recognize identical RNA substrates which are, however, saturated with signaling-deficient RIG-I Δ2CARD (E373Q) at higher transfected DNA concentrations thus preventing an immune response. Furthermore, we can exclude the possibility that the RIG-I C268F SMS mutation leads to a liberation of the 2CARD signaling module in the absence of RNA, for example by unfolding SF2. Instead, signaling by the RIG-I C268F SMS variant is dependent on 2CARD release triggered by binding to RNA molecules, as it is in wild type RIG-I.

![The RIG-I Singleton-Merten syndrome variant C268F signals in response to endogenous dsRNA.\
(**A**) Fold change of interferon (IFN)-β promoter-driven luciferase activity in uninfected HEK293T RIG-I KO cells or in cells stimulated with a 19mer 5'-triphosphate (ppp)-dsRNA upon overexpression of different RIG-I mutants. Cells were co-transfected with RIG-I expression vectors and p-125luc/pGL4.74 reporter plasmids, and stimulated with ppp-dsRNA 6 hr post transfection. Firefly luciferase activities were determined in respect to Renilla luciferase activities 16 hr after RNA stimulation. All ratios were normalized to an empty vector control. n = 4--12, error bars represent mean values + standard error of the mean (SEM). (**B**) Fluorescence anisotropy changes measured after titrating RIG-I or RIG-I C268F in the presence or absence of ATP into solutions containing a fluorescently labeled 14mer dsRNA. All binding curves were fit to a one-site binding equation using R. n = 4, error bars represent mean values ± standard deviation (SD).](elife-38958-fig1){#fig1}

To validate the intact RNA-binding properties of RIG-I C268F, we performed in vitro fluorescence anisotropy assays of purified proteins with a labeled hairpin (hp) RNA containing non-base-paired RNA ends ([Figure 1B](#fig1){ref-type="fig"}). We chose to use a double-stranded RNA ligand without blunt ends to suppress the dominant binding of RIG-I's RD to terminal RNA base pairs and to simulate recognition of endogenous-like RNA species that could be present within the cytosol. As expected, wild type RIG-I shows a moderate binding affinity to this ligand that is further decreased in the presence of ATP. By contrast, RIG-I C268F displays an already increased affinity to the hpRNA that is even enhanced in the presence of ATP. This confirms the previous results for RIG-I C268F showing an increased co-purification with endogenous RNA molecules ([@bib19]) and indicates that RIG-I C268F has two conformations (apo and ATP-bound) that have increased dsRNA affinity.

Since an intact SF2 ATPase domain of RIG-I is needed so that signaling only occurs when foreign RNA molecules are recognized ([@bib22]; [@bib30]), we further analyzed the ATP binding and hydrolysis properties of RIG-I C268F in vitro. The ATP-binding-deficient and hydrolysis-deficient motif I mutant RIG-I K270I and the hydrolysis-deficient motif II mutant RIG-I E373Q both served as references. ATP hydrolysis assays with ^32^P-labeled ATP confirmed a loss of catalytic activity of RIG-I C268F and of both motif I and II mutants in the presence of dsRNA ([Figure 2A](#fig2){ref-type="fig"}). In accordance with our RNA-binding experiments, this evidence supports a model in which RIG-I C268F has defects in dissociating from endogenous RNA, because it lacks the capability for ATP turnover and hence translocation. To further analyze the ATP-binding properties of the RIG-I SMS variant, we conducted a tryptophan fluorescence-based FRET assay with MANT-ATP ([@bib30]) ([Figure 2B](#fig2){ref-type="fig"}). In the absence of any RNA ligand, both wild type RIG-I and ATP-hydrolysis-deficient RIG-I E373Q show comparable affinities for MANT-ATP and MANT-ATPγS in the low µM range ([Table 1](#table1){ref-type="table"}). As expected, ATP-binding-deficient RIG-I K270I has a reduced affinity for ATP (in the medium µM range). In accordance with previous data ([@bib17]), the presence of RNA increases the affinity of wtRIG-I and RIG-I E373Q, but not of RIG-I K270I for MANT-ATP or MANT-ATPγS. Interestingly, like RIG-I K270I, the RIG-I SMS variant C268F displays reduced ATP-binding affinities compared to that of wtRIG-I or RIG-I E373Q independently of the availability of an RNA ligand ([Figure 2B](#fig2){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). This is puzzling as both RNA and ATP binding are normally needed to induce a molecular switch within RIG-I in order to release the 2CARD module and to activate an immune response ([@bib39]; [@bib47]). RIG-I C268F might thus be able to signal even in the absence of a bound ATP molecule. However, even though it is possible that under cellular conditions of 1 mM ATP or even higher, ATP is still bound by both motif I mutants, the molecular switch to release 2CARD is only triggered in RIG-I C268F but not in RIG-I K270I ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). These peculiarities of the ATP-bound states of the motif I mutants need to be addressed in future studies.

![The RIG-I Singleton-Merten syndrome variant C268F is catalytically dead and has reduced ATP-binding-properties.\
(**A**) ATP hydrolysis activity of RIG-I, the RIG-I Singleton-Merten syndrome (SMS) variant C268F and the RIG-I motif I and II mutants K270I and E373Q. RIG-I proteins were incubated with \[γ-^32^P\]-ATP in the presence or absence of a 12mer dsRNA for 15 min at room temperature and free phosphate was separated from ATP by thin layer chromatography. (**B**) Affinity of RIG-I, RIG-I C268F and the RIG-I motif I and II mutants to MANT-ATP or MANT-ATPγS measured by tryptophan fluorescence Förster resonance energy transfer to the MANT-nucleotide. Proteins were incubated with increasing amounts of nucleotides in the presence or absence of a 14mer dsRNA. MANT fluorescence was recorded minus a MANT-nucleotide-only control. n = 4, error bars represent mean values ± SD. (**C**) Fold change of interferon (IFN)-β promoter-driven luciferase activity in uninfected HEK293T RIG-I KO cells or in cells stimulated with a 19mer 5'-triphosphate (ppp)-dsRNA upon overexpression of different RIG-I mutants. Cells were co-transfected with RIG-I expression vectors and p-125luc/pGL4.74 reporter plasmids, and stimulated with ppp-dsRNA 6 hr post transfection. Firefly luciferase activities were determined in respect to Renilla luciferase activities 16 hr after RNA stimulation. All ratios were normalized to an empty vector control. n = 4--12, error bars represent mean values + SEM.](elife-38958-fig2){#fig2}
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###### Affinities of different RIG-I mutants to MANT-ATP or MANT-ATPγS in the presence or absence of a 14mer dsRNA. n.d., not determined, n.f., no fit possible as no saturation was reached.

  Protein             MANT-ATP      MANT-ATPγS
  ------------------- ------------- -------------
  RIG-I               72 ± 13 µM    58 ± 7 µM
  RIG-I + RNA         n.d.          11 ± 1 µM
  RIG-I E373Q         72 ± 13 µM    n.d
  RIG-I E373Q + RNA   28 ± 5 µM     n.d
  RIG-I K270I         298 ± 81 µM   n.d
  RIG-I K270I + RNA   n.f.          n.d
  RIG-I C268F         166 ± 34 µM   116 ± 13 µM
  RIG-I C268F + RNA   n.f.          147 ± 55 µM

To further investigate the influence of ATP binding to RIG-I C268F, we mutated two residues that are implicated in ATP adenine recognition, R244A and Q247A ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), thereby further lowering the ATP-binding affinity of the SMS mutant, and tested the ability of the resulting triple-mutant to induce an immune response ([Figure 2C](#fig2){ref-type="fig"}). We expected to see no decrease in the autoimmune signaling activity of the triple-mutant compared to that of the RIG-I SMS single-mutant if the single mutant was not able to bind ATP under cellular conditions. However, compared to the SMS variant itself, the IFN-β promoter activity of the ATP-binding mutant RIG-I R244A, Q247A, C268F was reduced, albeit still significantly higher than that of wild type RIG-I. Hence, these data support a model in which RIG-I C268F is able to release its 2CARD domain and start a signaling cascade by a process that is at least partly independent of ATP.

In order to elucidate the molecular basis of autoimmune signaling by RIG-I C268F, we went on to crystalize RIG-I Δ2CARD C268F in the presence of a 14mer dsRNA and ADP·BeF~x~ or ATP and determined the corresponding structures ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Intriguingly, despite an overall high structural similarity to wtRIG-I Δ2CARD bound to dsRNA ([@bib14]), the SMS mutant shows crucial amino acid side chain rearrangements in the active site that stabilize the protein in an activated state but prevent binding and co-crystalization of a nucleotide ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). In particular, the bulky F268 side chain displaces the evolutionary invariant motif I K270 from its central ATP phosphate-binding position in the P-loop, into a position where the Nε of K270 is situated at a site normally occupied by the Mg^2+^ ion ([Video 1](#video1){ref-type="video"}). As a result, K270 now forms a salt bridge with E702 from the C-terminal RecA-like domain 2A, which in turn occupies the ATP γ-phosphate binding site. The resulting overall conformation resembles the ATP-bound state of RIG-I, but without ATP, and could thus explain how C268F is able to signal independently of any nucleotide. In order to clarify the impact of the salt bridge, we mutated both side chains in RIG-I C268F and analyzed the resulting double-mutants in our IFN-β promoter activity assay ([Figure 3B](#fig3){ref-type="fig"}). We expected that a disturbance of the salt-bridge formation in RIG-I C268F would lead to a loss of autoimmune signaling. Indeed, mutation of K270 in RecA-like domain A1 renders RIG-I C268F inactive, probably as the result of a mixture of (i) prevention of the activation of RIG-I C268F in the absence of ATP by disrupting the salt bridge, and/or (ii) the failure to bind ATP altogether through impaired ATP phosphate coordination and thus an impaired 2CARD release. In contrast to our ATP-binding triple mutant R244A, Q247A, C268F, which still allows formation of the salt bridge in the absence of ATP, mutation of motif I K270 in RIG-I C268F thus renders the protein inactive. Mutation of E702 in the RecA-like domain 2A of RIG-I C268F, by contrast, does not disrupt constitutive signaling of the protein, although this activity is at a reduced level compared to that of RIG-I C268F. An explanation for this might be E702\'s localization within the SF2 helicase motif V, which couples RNA-binding-induced ATP hydrolysis with movement on dsRNA. Similar to our previously described V699A mutant in the same motif ([@bib19]), E702A alone already induces an autoimmune phenotype similar to that induced by RIG-I C268F, E702A. The most plausible explanation for these data is that RIG-I C268F stabilizes an ATP-like state in the absence of ATP, but still allows formation of a proper ATP-bound state. Although E702A could reduce the former (by disrupting the salt bridge), it might stabilize the latter by sterically allowing ATP binding or by increasing the interaction with RNA.

![The RIG-I Singleton-Merten syndrome variant C268F induces amino acid side chain rearrangements within the active site that interfere with nucleotide binding.\
(**A**) ATP-binding pockets of the RIG-I Singleton-Merten syndrome (SMS) variant C268F (left and middle panels) and the RIG-I wild type (right panel) bound to a 14mer dsRNA. The RIG-I SF2 sub-domains are colored in light gray or light blue (1A and 2A) and dark blue (2B). The RD is depicted in cyan and 2CARD is indicated in yellow. (**B**) Fold change of interferon (IFN)-β promoter-driven luciferase activity in uninfected HEK293T RIG-I KO cells or in cells stimulated with a 19mer 5'-triphosphate (ppp)-dsRNA upon overexpression of different RIG-I mutants. Cells were co-transfected with RIG-I expression vectors and p-125luc/pGL4.74 reporter plasmids, and stimulated with ppp-dsRNA 6 hr post transfection. Firefly luciferase activities were determined in respect to Renilla luciferase activities 16 hr after RNA stimulation. All ratios were normalized to an empty vector control. n = 4--12, error bars represent mean values + SEM.](elife-38958-fig3){#fig3}

###### Crystal structure of RIG-I Δ2CARD C268F and close-up of the active site.

The Singleton-Merten syndrome (SMS) mutation F268, as well as K270 and E702, are represented by a stick model. Theoretic locations of ADP·BeF~3~ and Mg^2+^ are indicated in faint sticks and spheres, respectively, according to a superposition with RIG-I Δ2CARD in complex with RNA and nucleotide analogue (PDB 5E3H). K270 is located at the Mg^2+^-binding site, whereas E702 occupies the BeF~3~ (ATP γ-phosphate) position.

10.7554/eLife.38958.010

In summary, our data suggest that the RIG-I C268F SMS mutation stabilizes the signal-on state of RIG-I in the presence of RNA but absence of ATP through a salt bridge between K270 from domain 1A and E702 from 2A. Unlike wild type RIG-I, which requires both RNA and ATP bound in order to be activated for downstream signaling, RIG-I C268F can signal independently of ATP ([Figure 2C](#fig2){ref-type="fig"}) in the presence of RNA ([Figure 1A](#fig1){ref-type="fig"}). However, our data also show that ATP further increases the binding of RIG-I C268F to internal dsRNA stems ([Figure 1B](#fig1){ref-type="fig"}) and that the engineering of ATP-binding mutations R244A, Q247A into RIG-I C268F at least partly reduces its signaling activity in response to endogenous or ppp-dsRNA RNA ([Figure 2C](#fig2){ref-type="fig"}). Even though we were not able to co-crystalize RIG-I C268F in the presence of a nucleotide, it is very possible that binding of ATP at high molecular concentrations, such as those present in a cellular context, further contributes to the pathogenic signaling activity of the protein. In principle, ATP binding would be sterically allowed if the salt-bridge-forming residue E702 occupies a site as in wtRIG-I. It is not yet clear what happens at the Mg^2+^-binding site, as sterically F268 would not allow a canonical positioning of motif I K270 and might thus prevent binding of Mg^2+^. Perhaps K270 remains at the displaced site even in the presence of ATP and simply 'mimics' Mg^2+^. Such a scenario could still lead to reduced binding of ATP but would prevent ATP hydrolysis, as observed, because of a substantially altered charge distribution. This mechanism unifies the molecular basis for the development of SMS by both RIG-I variants ([Figure 4](#fig4){ref-type="fig"}). Unlike wtRIG-I, which consumes ATP and uses ATP turnover to decrease its affinity to self-RNA ([Figure 4A](#fig4){ref-type="fig"}), both motif I and II SMS mutations either mimic or freeze RIG-I in an ATP-bound state ([Figure 4B](#fig4){ref-type="fig"}). As a consequence, the inability to hydrolyze ATP and thus to dissociate actively from RNA ([Figure 1B](#fig1){ref-type="fig"}, [Figure 2A](#fig2){ref-type="fig"}) traps the protein in an activated state and thus explains autoimmune signaling in response to self-RNA.

![Model for the impact of Singleton-Merten syndrome mutations on self-RNA-induced RIG-I signaling.\
(**A**) In healthy cells, wild type RIG-I occurs in a signal-off state in which 2CARD is shielded by binding to the insertion domain of SF2. Binding of RIG-I to self-RNAs is efficiently prevented through ATP-turnover-induced dissociation (for a detailed model on self- vs non-self RNA discrimination see also [@bib19]. (**B**) RIG-I Singleton-Merten syndrome (SMS) mutations either slow down ATP hydrolysis and stabilize the ATP-state (E373A, left side) or mimic the ATP-bound state (C268F, right side), and thus allow formation of the RIG-I signal-on state. In both cases, loss of ATP hydrolysis enhances the interaction with self-RNA and therefore results in pathogenic signaling. SMS mutations are indicated with a yellow or orange star.](elife-38958-fig4){#fig4}

In conclusion, we provide for the first time a detailed biochemical and structural analysis of an RLR autoimmune disease variant. Slight intramolecular rearrangements within the RIG-I C268F ATP-binding pocket appear to compensate for ATP binding and render the protein active in the presence of dsRNA only. At the same time, loss of proof-reading activity leads to increased activation by endogenous RNA. This unusual gain-of-function mutation reveals, for the first time to our knowledge, that a P-loop mutation can mimic the effects of ATP binding.

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\    Designation               Source or reference   Identifiers                                                    Additional information
  or source                                                                                                                                 
  -------------------------- ------------------------- --------------------- -------------------------------------------------------------- ---------------------------------------
  Cell line (human)          HEK293T RIG-I KO          [@bib48]                                                                             Growth in Dulbecco\'s Modified Eagle\
                                                                                                                                            Medium (DMEM) supplemented with\
                                                                                                                                            10% fetal bovine serum (FBS) as\
                                                                                                                                            monolayer

  Strain, strain\            BL21 (DE3) Rosetta        Novagene                                                                             
  background\                                                                                                                               
  (*Escherichia coli*)                                                                                                                      

  Strain, strain\            DH10multiBac              GenevaBiotech                                                                        
  background\                                                                                                                               
  (*Escherichia coli*)                                                                                                                      

  Strain, strain\            Sf21 insect cells         Thermo Fisher\        11497013                                                       Growth in SF-900 III\
  background\                                          Scientific                                                                           serum-free medium
  (*Spodoptera frugipeda*)                                                                                                                  

  Strain, strain\            High Five insect cells    Thermo Fisher\        B85502                                                         Growth in Express Five serum-free\
  background\                                          Scientific                                                                           medium supplemented with\
  (*Trichoplusia ni*)                                                                                                                       10 mM L-glutamine

  Recombinant\               pcDNA5/FRT/TO             Thermo Fisher\        V652020                                                        
  DNA reagent                                          Scientific                                                                           

  Recombinant\               pcDNA5/FRT/TO-FLAG/\      [@bib19]\                                                                            Progenitors: PCR, DDX58\
  DNA reagent                HA-RIG-I and various\     and this paper                                                                       (cDNA) and pcDNA5/FRT/TO
                             mutants of the same\                                                                                           
                             construct                                                                                                      

  Recombinant\               p-125luc                  [@bib45]                                                                             Firefly luciferase controlled\
  DNA reagent                                                                                                                               by an interferon-β promoter

  Recombinant\               pGL4.74                   Promega               E6921                                                          Constitutive expression of a\
  DNA reagent                                                                                                                               Renilla luciferase

  Recombinant\               pFBDM                     [@bib4]                                                                              
  DNA reagent                                                                                                                               

  Recombinant\               pFBDM-His-RIG-I\          [@bib19]\                                                                            Progenitors: PCR, DDX58 (cDNA)\
  DNA reagent                and various mutants of\   and this paper                                                                       and pFBDM
                             the same construct                                                                                             

  Recombinant\               pETM11-SUMO3GFP           EMBL Heidelberg,\     <https://www.embl.de/pepcore/pepcore_services/cloning/sumo/>   
  DNA reagent                                          H. Besir                                                                             

  Recombinant\               pETM11-SUMO3-RIG-I-\      This paper                                                                           Progenitors: PCR, DDX58\
  DNA reagent                Δ2CARD-C268F                                                                                                   (cDNA) and pETM11-SUMO3GFP

  Sequence-based\            19mer 5\' triphosphate\   InvivoGen             tlrl-3prna                                                     1 µg/mL, 5'-pppGCAUGC\
  reagent                    dsRNA                                                                                                          GACCUCUGUUUGA-3

  Sequence-based\            14mer dsRNA               Dharmacon                                                                            5\'-CGACGCUAGCGUCG-3\'
  reagent                                                                                                                                   

  Sequence-based\            Cy3-hpRNA                 Biomers                                                                              5\'-Cy3-CCACCCGCCCCCCUAGU\
  reagent                                                                                                                                   GAGGGGGGCGGGCC-3\'

  Chemical\                  Lipofectamine 2000        Thermo Fisher\        11668019                                                       Used at 2.5x excess compared\
  compound, drug                                       Scientific                                                                           to RNA/DNA mass

  Chemical\                  MANT-ATP                  Jena Bioscience       NU-202                                                         
  compound, drug                                                                                                                            

  Chemical\                  MANT-ATPγS                Jena Bioscience       NU-232                                                         
  compound, drug                                                                                                                            

  Chemical\                  \[γ-^32^P\]ATP            Hartmann Analytic     SRP-301                                                        10 nM spiked with\
  compound, drug                                                                                                                            3 mM unlabeled ATP

  Commercial\                Dual-Luciferase\          Promega               E1910                                                          
  assay or kit               Reporter Assay\                                                                                                
                             System                                                                                                         

  Software,\                 XDS, XSCALE               [@bib16]              <http://xds.mpimf-heidelberg.mpg.de/>                          
  algorithm                                                                                                                                 

  Software,\                 PHASER                    [@bib24];\            <http://www.ccp4.ac.uk/>                                       
  algorithm                                            [@bib42]                                                                             

  Software,\                 Coot                      [@bib10]              <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>        
  algorithm                                                                                                                                 

  Software,\                 PHENIX                    [@bib1]               <https://www.phenix-online.org/>                               
  algorithm                                                                                                                                 

  Software,\                 Pymol                     Schrödinger           <https://pymol.org/2/>                                         
  algorithm                                                                                                                                 

  Software,\                 R                         [@bib29]              <https://www.r-project.org/>                                   
  algorithm                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vectors and cell lines {#s3-1}
----------------------

Sequences encoding full-length (1-925) or N-terminal truncated (230--925 or 232--925) human RIG-I were cloned into either pcDNA5/FRT/TO (purchased from Thermo Fisher Scientific, Waltham, MA; for expression in human cells), pFBDM (for expression in insect cells) ([@bib4]) or pETM11-SUMO3 (EMBL, Heidelberg, Germany; for expression in *E. coli*). All proteins that were overexpressed in human cells contained an N-terminal FLAG/HA-tag, whereas proteins purified from insect cells contained an N-terminal His-tag.

Mutants were generated by site-directed mutagenesis using the QuikChange protocol and PfuUltra polymerase (Agilent, Santa Clara, CA).

HEK293T RIG-I KO cells ([@bib48]) were maintained in high glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with GlutaMAX, pyruvate and 10% fetal bovine serum (FBS) (all purchased from Thermo Fisher Scientific, Waltham, MA) at 37°C/ 5% CO~2~ and were regularly tested by PCR for potential mycoplasma contaminations. *Spodoptera frugipeda* Sf21 and *Trichoplusia ni* High Five insect cells were maintained at 27°C/ 150 rpm in SF-900 III serum-free medium and High Five serum-free medium supplemented with 10 mM L-glutamine, respectively (both purchased from Thermo Fisher Scientific, Waltham, MA).

Luciferase reporter-gene assays {#s3-2}
-------------------------------

Transfection-based reporter gene assays in HEK293T RIG-I KO cells were carried out in 96-well tissue culture plates seeded with 0.2 × 10^5^ cells one day prior to transfection. Cells were transfected with 25 ng p-125Luc (inducible-expression of a Firefly luciferase controlled by an interferon-β promoter) ([@bib45]), 5 ng pGL4.74 (constitutive-expression of Renilla luciferase, Promega, Madison, WI) and varying concentrations of FLAG/HA-RIG-I plasmids (1--200 ng) in a total amount of 300 ng DNA per well (filled up with empty pcDNA5 FRT/TO) using OptiMEM and Lipofectamine 2000 (both Thermo Fisher Scientific, Waltham, MA) according to the vendor's protocol. After 6 hr, cells were either stimulated by transfection of 1 µg/mL 19mer 5'triphosphate-dsRNA (InvivoGen, San Diego, CA) in OptiMEM using Lipofectamine 2000 or the respective amount of OptiMEM alone was added. Cells were harvested 16 hr after RNA stimulation in 50 µL passive lysis buffer (Promega, Madison, WI) and frozen at −20°C until they were used. Luciferase activities were determined with a Berthold Luminometer in black 96-well plates using 20 µL cell lysate and the Dual-Luciferase Reporter Assay System (Promega, Madison, WI).

For competition assays of FLAG/HA-RIG-I C268F with N-terminally shortened FLAG/HA-RIG-I Δ2CARD (230-925), cells were seeded as described above. Cells were transfected with 25 ng p-125Luc, 5 ng pGL4.74, 75 ng FLAG/HA-RIG-I C268F plasmid and varying concentrations (1--195 ng) of competitor plasmids containing N-terminal truncated RIG-I in a total of 300 ng DNA per well (filled up with empty pcDNA5 FRT/TO) using OptiMEM and Lipofectamine 2000 as transfection reagent according to the vendor's protocol. Cells were harvested 16 hr after transfection in 50 µL passive lysis buffer and frozen at −20°C. Luciferase activities were determined as described above.

All cell-based assays were performed at least four times in independent experiments and are represented as mean values + SEM.

Protein expression and purification {#s3-3}
-----------------------------------

Recombinant full-length human RIG-I or RIG-I single amino acid mutants (1--925, N-terminal His-tag) were produced in and purified from High Five insect cells as described before ([@bib7]; [@bib19]; [@bib30]). Briefly, the open reading frame for human RIG-I was cloned into the pFBDM vector, transformed into *E. coli* DH10MultiBac, and extracted Baculovirus DNA was then transfected into SF21 insect cells. Baculoviruses were propagated twice in SF21 insect cells and subsequently used for infection of High Five insect cells. Expression was carried out for 3 days at 27°C. Harvested cells were shock frozen in liquid nitrogen and stored at −20°C until they were used. For purification, cells were resuspended in lysis buffer (25 mM HEPES, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 5 mM β-mercaptoethanol, pH 7) and lyzed by sonication. Cleared lysate was loaded onto Ni-NTA agarose resin (Qiagan, Hilden, Germany), washed with lysis buffer containing 300 mM NaCl and eluted in elution buffer (25 mM HEPES, 100 mM NaCl, 200 mM imidazole, 10% glycerol, 5 mM β-mercaptoethanol, pH 7). Proteins were further purified on a HiTrap Heparin HP column (GE Healthcare, Little Chalfont, UK) in 25 mM HEPES, 10% glycerol, 5 mM β-mercaptoethanol, pH 7 using a linear salt gradient ranging from 100 mM to 1 M NaCl. Finally, fractions containing RIG-I were pooled and loaded onto a HiLoad Superdex 200 16/60 size exclusion column (GE Healthcare, Little Chalfont, UK) using gel filtration buffer (25 mM HEPES, 150 mM NaCl, 5 mM MgCl~2~, 5% glycerol, 5 mM β-mercaptoethanol, pH 7). Monomeric RIG-I was concentrated to \~6 mg/mL, flash frozen in liquid nitrogen and stored at −80°C. N-terminally truncated RIG-I Δ2CARD C268F (232--925, N-terminal His-tag) expressed in High Five cells was purified as described above.

In addition, N-terminally truncated RIG-I Δ2CARD C268F (232--925, N-terminal His-Sumo3-tag) was produced in and purified from *E. coli* Rosetta (DE3). Cells were induced with 0.2 mM DTT at an OD~600~ of 0.6--0.8 and protein was expressed at 18°C overnight. Harvested cells were shock frozen in liquid nitrogen and stored at −20°C. Protein was purified as described above, except that after metal affinity chromatography, the His-SUMO-tag was cleaved off by adding SenP2 protease (mass ratio 1:500) to pooled eluate fractions during a dialysis step against elution buffer without imidazole (25 mM HEPES, 100 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, pH 7) that was carried out overnight at 4°C. Cleaved protein was separated from the tag during a second metal-affinity chromatography by step-wise elution with elution buffers containing 20 mM and 40 mM imidazole, and subjected to heparin-affinity and gel-filtration chromatography as described above.

For crystalization, N-terminally truncated RIG-I Δ2CARD C268F (purified either from insect cells or from *E. coli*) was concentrated to \~25 mg/mL.

Protein crystalization {#s3-4}
----------------------

Co-crystalization of RIG-I Δ2CARD C268F (170 µM) with equimolar concentrations of 14mer dsRNA (5\'-CGACGCUAGCGUCG-3\', palindromic RNA, purchased from Dharmacon, Lafayette, CO) was done either in the presence of 2 mM ADP, 2 mM BeCl~2~ and 10 mM NaF to reconstitute ADP·BeF~x~ (crystal 1) or with 2 mM ATP (crystal 2) by hanging-drop vapor diffusion at 20°C. In each case, 2.5 µL protein/RNA/nucleotide mix was added to 2.5 µL reservoir solution from a total reservoir volume of 400 µL per well. Crystal 1 was raised in wells containing 0.1 M MOPS pH 7.5, 15% (w/v) PEG 3350, 0.125 M NaSCN and 3% (v/v) 2,2,2-trifluoroethanol as reservoir solution. The reservoir of crystal 2 contained 0.1 M MOPS pH 7.5, 17.5% (w/v) PEG 3350, 0.25 M NaSCN and 3% (v/v) 2,2,2-trifluoroethanol. Crystals appeared after 1--2 days and were transferred into the respective reservoir solutions containing 10% (v/v) 2,3-butanediol as cryoprotectant, flash-frozen and stored in liquid nitrogen.

Data collection and structure determination {#s3-5}
-------------------------------------------

X-ray diffraction data were collected at the SLS X06SA beamline (Swiss Light Source, Villigen, Switzerland). Diffraction datasets from both crystals were indexed and integrated using XDS and scaled with XSCALE ([@bib16]). Crystal 1 had space group P2~1~2~1~2~1~ and diffracted to 3.3 Å, crystal 2 had space group P6~5~22 and diffracted until 2.9 Å ([Table 2](#table2){ref-type="table"}). Diffraction data from crystal 1 were used to determine an initial structure of RIG-I Δ2CARD C268F by molecular replacement using PHASER ([@bib24]; [@bib42]) and a search model based on a published structure of RIG-I Δ2CARD (PDB entry 5E3H) ([@bib14]). The initial model was created in two iterative rounds of manual model building and refinement using Coot and PHENIX ([@bib1]; [@bib10]). This model was used to phase the second, better-diffracting dataset from crystal 2 using PHASER. The final structure was built and refined in several iterative rounds using Coot and PHENIX. The statistics describing both structures are shown in ([Table 2](#table2){ref-type="table"}). We did not detect any density for a bound nucleotide in either structure.
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###### Data collection and refinement statistics.

Values in parentheses are for the highest resolution shell.

                            **Crystal 1**            **Crystal 2**
  ------------------------- ------------------------ ------------------------
  **PDB code**                                       6GPG
  **Data collection**                                
  Space group               P2~1~2~1~2~1~            P6~5~22
  Wavelength (Å)            1.00                     1.00
  Cell dimensions                                    
  *a*, *b*, *c* (Å)         112.1, 177.1, 314.8      175.6, 175.6, 109.5
  *α*, β, γ (°)             90, 90, 90               90, 90, 120
  Resolution range (Å)      47.2--3.3 (3.42--3.30)   46.4--2.9 (3.00--2.89)
  *R*~merge~ (%)            14.3 (112)               7.6 (206)
  *I*/σ*I*                  8.45 (1.28)              19.72 (1.15)
  *CC*~1/2~                 99.8 (67.6)              99.9 (99.7)
  Completeness (%)          95.3 (79.7)              99.7 (97.4)
  Redundancy                3.38 (2.91)              13.09 (13.21)
  **Refinement**                                     
  Resolution (Å)            3.3                      2.9
  No. reflections           90,121                   22,649
  *R*~work/~ *R*~free~      22.8/28.3                21.4/25.9
  No. atoms                                          
   Macromolecules           35,730                   5,810
   Ions                     10                       2
  Ramachandran statistics                            
   Favoured (%)             92.78                    92.71
   Allowed (%)              6.39                     6.98
   Outliers (%)             0.83                     0.31
  R.M.S deviations                                   
   Bond lengths (Å)         0.011                    0.009
   Angles (°)               1.48                     1.43
  B-factors                                          
   Macromolecules           109.98                   139.89
   Ions                     105.23                   121.74

Figures and movies were created with PyMOL ([@bib37]).

ATP hydrolysis assays {#s3-6}
---------------------

ATP hydrolysis activities of different full-length His-RIG-I constructs were determined using \[γ-^32^P\]ATP (Hartmann Analytic, Braunschweig, Germany). 100 nM protein was pre-incubated with 100 nM 12mer 5'triphosphate-dsRNA for 10 min at room temperature in hydrolysis buffer (25 mM HEPES, 50 mM KCl, 5 mM MgCl~2~, 5 mM TCEP, pH 7.5). The reaction was initiated by the addition of 3 mM unlabeled and 10 nM \[γ-^32^P\]ATP and incubated for 15 min at 37˚C. Free phosphate was separated from ATP by thin layer chromatography (TLC) in TLC running buffer (1 M formic acid, 0.5 M LiCl) on polyethyleneimine cellulose TLC plates (Sigma-Aldrich, St. Louis, MO). \[γ-^32^P\]P~i~ and \[γ-^32^P\]ATP were detected using the Typhoon^TM^ FLA 9500 phosphor-imaging system (GE Healthcare, Little Chalfont, UK).

Fluorescence anisotropy {#s3-7}
-----------------------

Affinities of full-length RIG-I or RIG-I C268F (1--925, N-terminal His-tag) to a Cy3-labeled hpRNA (5\'-Cy3-CCACCCGCCCCCCUAGUGAGGGGGGCGGGCC-3\', purchased from Biomers, Ulm, Germany) were determined using fluorescence anisotropy. All samples were prepared in 96-well black chimney microplates (Greiner Bio-One, Kremsmünster, Austria). 10 nM RNA was pre-incubated with different protein concentrations (2.4 nM -- 5 µM) for 15 min at room temperature in assay buffer (25 mM HEPES, 50 mM KCl, 5 mM MgCl~2~, 1 mM DTT, pH 7). Fluorescence anisotropy was measured after the addition of 5 mM ATP using a TECAN M1000 microplate reader (Tecan, Männedorf, Switzerland) at λ~ex~/~em~ = 530/570 nm and gain = 130 during a time course of 25 min in 1 min intervals. Assays were performed four times in independent experiments using the same protein purification batch. For determination of affinities, anisotropy values between 15 and 20 min measuring time were averaged and fit to the following single-site binding model using R ([@bib29]):$$y = B_{max}\frac{\left\lbrack P \right\rbrack}{\left\lbrack P \right\rbrack + K_{D}}$$where y is the observed anisotropy, \[P\] is the protein concentration, B~max~ is the maximal anisotropy and K~D~ is the dissociation constant. Fitting was performed globally on all available datasets. Representative values in figures are mean values ± SD.

MANT-ATP binding {#s3-8}
----------------

Binding of MANT-ATP and MANT-ATPγS to different full-length RIG-I mutants (1--925, N-terminal His-tag) was determined via Förster resonance energy transfer from RIG-I to MANT-ATP (Jena Bioscience, Jena, Germany). All samples were prepared in 96-well black chimney microplates. 2.2 µM protein and equimolar concentrations of a 14mer dsRNA (5\'-CGACGCUAGCGUCG-3\', see \'Protein crystalization\') were pre-incubated with different MANT-ATP concentrations (0.2 µM -- 200 µM) for 15 min at room temperature in assay buffer (25 mM HEPES, 50 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, pH 7). Fluorescence of MANT-ATP was measured in a TECAN M1000 microplate reader at λ~ex~/~em~ = 290/448 nm, gain = 170 using an average of five reads per well. Assays were performed four times in independent experiments using the same protein purification batch. For determination of affinities fluorescence values were fitted to [Equation (1)](#equ1){ref-type="disp-formula"} using R, where y is the fluorescence, \[P\] is the protein concentration, B~max~ is the maximal fluorescence and K~D~ is the dissociation constant. Fitting was performed globally on all available datasets. Representative values in figures are mean values ± SD.
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Diffraction data have been deposited in PDB under the accession code 6GPG.

The following dataset was generated:

Lässig CLammens KHopfner KP2018Structure of the RIG-I Singleton-Merten syndrome variant C268F<https://www.ebi.ac.uk/pdbe/entry/pdb/6gpg>Publicly available at the RCSB Protein Data Bank (accession no. 6GPG)

The following previously published dataset was used:

Jiang FMiller MTMarcotrigiano J2015Structural Basis for RNA Recognition and Activation of RIG-I<https://www.rcsb.org/structure/5E3H>Publicly available at the RCSB Protein Data Bank (accession no. 5E3H)
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Thank you for submitting your article \"Unified mechanisms for self-RNA recognition by RIG-I Singleton-Merten syndrome variants\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and John Kuriyan as the Senior Editor. The following individual involved in review of your submission has agreed to reveal her identity: Sua Myong (Reviewer \#1).

This is an interesting novel extension of their prior publication in *eLife*, structurally rationalizing the behavior of a disease-causing mutation in RIG-I.

This manuscript is acceptable without further review, but some textual clarification is requested. The authors should consider whether to do this, and if they feel that these changes would improve their manuscript they should make the changes. The revised manuscript will be accepted with a minimum of editorial intervention, without further reviewer input.

1\) The manuscript is written in a condensed manner i.e., there are many mutants and various assays presented in the manuscript. It will be great if the authors can take time to explain why each mutant was made and what the expected result vs. experimental outcome was.

2\) Despite the structural data in support of this idea, the ATP-independent mode of activity is less certain. It is very difficult to prove that ATP is not binding under cellular conditions. C268F is likely bound to ATP in the cell due to the high concentration of ATP (1 mM or higher), even in consideration of the binding data in Figure 2B. Binding of C268F to ATP is weak, but clearly observable. Some qualification should be noted.

*Reviewer \#1:*

This is an exciting study presented by the Hopfner lab. RIG-I is a major antiviral innate immune sensor which distinguishes self- from viral RNA by recognizing the 5\'-triphosphate moiety, a unique molecular signature of viral RNA. Moreover, the ATP dependent translocation activity and the subsequent release of the protein is important for discriminating the self-RNA. Understanding the mechanism by which RIG-I acts to transmit innate immune signaling is critical, especially in light of severe mutations that occur in Singleton Merton Syndrome. In this study, the authors performed a series of thorough biochemical analysis of one of the poorly understood SMS variants, C268F which causes constitutive immune activation. They explain the biochemical defect of C268F by structural analysis of the protein. The combined analysis points toward a clear structural basis of the mutant phenotype. Impressively, the authors compared three different mutants including previously characterized E373A and K270I to the current mutant, C268F. A clever approach of creating double mutant C268F/T347A demonstrated that RNA binding is still required for IFN-β induction i.e. immune activation by C268F. Both the apo and ATP-bound form of C268F mutants exhibited increased RNA binding affinity although the mutant had reduced affinity for ATP and deficient at ATP hydrolysis. Additional mutations, R244A and Q247A which further reduced ATP binding affinity still induced comparable level of immune signaling. Taken together, the C268F mutant is capable of constitutive antiviral signaling when bound to any RNA, even without ATP binding or ATP hydrolysis. The structure shows why. The C268F results in the formation of a special salt bridge in P-loop which leads to a conformation that mimics ATP bound state even in the absence of ATP. When the salt bridge is abolished, the constitutive effect disappears, signifying that the structural rearrangement induced by C268F is the key in creating an ATP bound conformation which induce the antiviral immune-signaling. The study is meticulously carried out, each hypotheses thoroughly tested and the structural result perfectly complements the biochemical data. The only point to be addressed is the following assays presented in the manuscript. It will be great if the authors can take time to explain why each mutant was made and what the expected result vs. experimental outcome was. I highly recommend publication of this work in *eLife*.

*Reviewer \#2:*

Previous work from some of these authors, published in *eLife*, indicated that RIG-I utilizes its ATP hydrolysis driven translocation on double-stranded RNA to distinguish self RNA from non-self RNA. The ATPase activity allowed the enzyme to rapidly translocate from self RNA while non-self dsRNA tended to slow the ATP hydrolysis thereby allowing more stable RNA binding and subsequent signaling of the innate immune pathway. In the current submission, the authors provide a possible structural mechanism for how a known mutation in RIG-I causes the Singleton-Merten autoimmune syndrome. Biochemical data indicate little or no ATP hydrolysis and low ATP binding of the C268F variant. Structural data indicates that C268F leads to arrangement of amino acids in the ATP binding site as if ATP is bound (but in the absence of ATP). This arrangement of amino acids and lack of ATP hydrolysis leads to continued immune signaling, or in other words, a \"gain-of-function\". The current work therefore builds upon the previous work by showing how a mutation can lead to immune activation by causing the enzyme to mimic a structural conformation that resembles the ATP-bound or \"activated\" conformation. Thus, C268F RIG-I is unable to translocate off of an RNA substrate (supported by binding data). The current data does appear to solidify the proposed mechanism involving the ATP binding and hydrolysis which is a significant advance.

Summary of Concerns:

An additional significant advance claimed by the authors is that the C268F mutation can lead to RIG-I being locked into an \"signal-on state\" even in the absence of ATP binding. Despite the structural data in support of this idea, the ATP-independent mode of activity is less certain. It is very difficult to prove that ATP is not binding under cellular conditions. C268F is likely bound to ATP in the cell due to the high concentration of ATP (1 mM or higher), even in consideration of the binding data in Figure 2B. Binding of C268F to ATP is weak, but clearly observable. The results with the double mutant C268F, K270I seem to support the idea that ATP binding is needed for activation of the immune response, because this double mutant displays very low immune activity and likely does not bind to ATP.

The concerns are balanced by high quality structural and solid biophysical work coupled with a gene expression reporter that supports the biophysical data. The RIG-I enzyme does appear to distinguish self RNA from non-self RNA through the activation or lack of activation of the ATP hydrolysis activity or through structural conformations that mimic these conformations. I am less sure of whether this occurs in complete absence of ATP binding.
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Author response

> This manuscript is acceptable without further review, but some textual clarification is requested. The authors should consider whether to do this, and if they feel that these changes would improve their manuscript they should make the changes. The revised manuscript will be accepted with a minimum of editorial intervention, without further reviewer input.
>
> 1\) The manuscript is written in a condensed manner i.e., there are many mutants and various assays presented in the manuscript. It will be great if the authors can take time to explain why each mutant was made and what the expected result vs. experimental outcome was.

We very much thank Sua Myong for her positive feedback on our manuscript and for this advice. We wrote the manuscript as condensed as possible in order to satisfy the 1500 word limit stated in the guidelines. Following the advice, we added further explanations detailing the rationale behind our experimental set-up and the interpretation of the outcome. Furthermore, we explained our mutants better in the supplemental figures Figure 1---figure supplement 1 and Figure 2---figure supplement 1. Here we show the location of all used mutations in more detail.

> 2\) Despite the structural data in support of this idea, the ATP-independent mode of activity is less certain. It is very difficult to prove that ATP is not binding under cellular conditions. C268F is likely bound to ATP in the cell due to the high concentration of ATP (1 mM or higher), even in consideration of the binding data in Figure 2B. Binding of C268F to ATP is weak, but clearly observable. Some qualification should be noted.

We also like to thank reviewer 2 for the valuable feedback and the argument concerning cellular ATP concentrations. We added a sentence mentioning cellular ATP concentrations within the passage describing the FRET ATP-binding assay (Results and Discussion, fourth paragraph) as well as within the discussion of our results (Results and Discussion, seventh paragraph).
